Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma
Journal of Extracellular Biology, Volume 5, Issue 7, July 2026.ABSTRACT Temozolomide (TMZ) is a first‐line chemotherapeutic agent for the treatment of glioblastoma (GBM), while a majority of patients do not effectively respond to TMZ owing to the multiple resistance mechanisms. In this study, we found that TMZ treatment substantially increased the exosome secretion from GBM cell line.
Wenpei Li +9 more
wiley +1 more source
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications. [PDF]
Transl OncolLi J +6 more
europepmc +1 more source
Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy
Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.ABSTRACT Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient
Cécile Acquaviva +5 more
wiley +1 more source
PARP-2 catalytic activity drives replication-ICL repair in an allele-specific manner during germline development. [PDF]
PLoS GenetRen X, Hu A, Liu Z, Kim S, Kim HM.
europepmc +1 more source
Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy
MedComm, Volume 7, Issue 7, July 2026.Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu +5 more
wiley +1 more source
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. [PDF]
Future OncolAzad AA +10 more
europepmc +1 more source
Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?
Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca +6 more
wiley +1 more source
Enhanced Antitumor Response in Breast Cancer via Parthanatos Activation Mediated by the Synergistic Effect of Etoposide and Resveratrol. [PDF]
Curr Issues Mol BiolTaghavi Pourianazar N, Abdullah N.
europepmc +1 more source
PROTEOMICS, Volume 26, Issue 7, Page 28-41, July 2026.ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free ...
Ha‐Song Bae +6 more
wiley +1 more source